Delivery of ALX-0171 by inhalation greatly reduces respiratory syncytial virus disease in newborn lambs

mAbs

Volumn 10, Issue 5, 2018, Pages 778-795

  Larios Mora, Alejandro ^a   Detalle, Laurent ^b   Gallup, Jack M ^a   Van Geelen, Albert ^a   Stohr, Thomas ^b   Duprez, Linde ^b   Ackermann, Mark R ^a  

^a IOWA STATE UNIVERSITY   (United States)

^b ABLYNX NV   (Belgium)

Author keywords

inhalation; lower respiratory tract infections; nanobody; nebulizer; neonatal lambs; RSV

Indexed keywords

ALX 0171; ANTIVIRUS AGENT; NANOBODY; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; HISTOPATHOLOGY; IC90; LAMB; LUNG LAVAGE; LUNG PARENCHYMA; NEBULIZATION; NEWBORN; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; ANIMAL; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODEL; DRUG EFFECT; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; INHALATIONAL DRUG ADMINISTRATION; LUNG; PATHOLOGY; PHYSIOLOGY; SHEEP; SHEEP DISEASE; VETERINARY MEDICINE; VIROLOGY;

ADMINISTRATION, INHALATION; ANIMALS; ANIMALS, NEWBORN; ANTIVIRAL AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; DISEASE MODELS, ANIMAL; HUMANS; INFANT; LUNG; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SHEEP; SHEEP DISEASES; SINGLE-DOMAIN ANTIBODIES; VIRAL LOAD;

EID: 85049589456     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2018.1470727     Document Type: Article

References (67)

1. Afonso CL, Amarasinghe GK, Bányai K, Bào Y, Basler CF, Bavari S, Bejerman N, Blasdell KR, Briand FX, Briese T, et al. Taxonomy of the order Mononegavirales: update 2016. Arch Virol. 2016;161(8):2351–60. doi:10.1007/s00705-016-2880-1. PMID:27216929
2. Everard M. Diagnosis, admission, discharge. Paediatr Respir Rev. 2009;10(Suppl 1):18–20. doi:10.1016/S1526-0542(09)70009-0. PMID:19651395
3. Fauroux B. Special populations. Paediatr Respir Rev. 2009;10(Suppl 1):21–2. doi:10.1016/S1526-0542(09)70010-7. PMID:19651396
4. Shi T., McAllister DA, O'Brien KL, Simoes EAF, Madhi SA, Gessner BD, Polack FP, Balsells E, Acacio S, Aguayo C, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946–58. doi:10.1016/S0140-6736(17)30938-8. PMID:28689664
5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. The N Engl J Med. 2005;352(17):1749–59. doi:10.1056/NEJMoa043951. PMID:15858184
6. Drysdale SB, Green CA, Sande CJ. Best practice in the prevention and management of paediatric respiratory syncytial virus infection. Ther Adv Infect Dis. 2016;3(2):63–71. doi:10.1177/2049936116630243. PMID:27034777
7. Resch B. Respiratory Syncytial Virus Infection in High-risk Infants–an Update on Palivizumab Prophylaxis. Open Microbiol J. 2014;8:71–7. doi:10.2174/1874285801408010071. PMID:25132870
8. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415–20. doi:10.1542/peds.2014-1665. PMID:25070315
9. Byrd LG, Prince GA. Animal models of respiratory syncytial virus infection. Clin Infect Dis. 1997;25(6):1363–8. doi:10.1086/516152. PMID:9431379
10. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol. 2011;301(2):L148–56. doi:10.1152/ajplung.00065.2011. PMID:21571908
11. Niewiesk S, Prince G. Diversifying animal models: the use of hispid cotton rats (Sigmodon hispidus) in infectious diseases. Lab Anim. 2002;36(4):357–72. doi:10.1258/002367702320389026. PMID:12396279
12. Boukhvalova MS, Prince GA, Blanco JC. The cotton rat model of respiratory viral infections. Biologicals. 2009;37(3):152–9. doi:10.1016/j.biologicals.2009.02.017. PMID:19394861
13. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol. 1986;57(3):721–8. PMID:2419587
14. Derscheid RJ, Gallup JM, Knudson CJ, Varga SM, Grosz DD, van Geelen A, Hostetter SJ, Ackermann MR. Effects of formalin-inactivated respiratory syncytial virus (FI-RSV) in the perinatal lamb model of RSV. PLoS One. 2013;8(12):e81472. doi:10.1371/journal.pone.0081472. PMID:24324695
15. Scheerlinck JP, Snibson KJ, Bowles VM, Sutton P. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol. 2008;26(5):259–66. doi:10.1016/j.tibtech.2008.02.002. PMID:18353472
16. Mechanisms and limits of induced postnatal lung growth. Am J Respir Crit Care Med. 2004;170(3):319–43. doi:10.1164/rccm.200209-1062ST. PMID:15280177
17. Derscheid RJ, Ackermann MR. Perinatal lamb model of respiratory syncytial virus (RSV) infection. Viruses. 2012;4(10):2359–78. doi:10.3390/v4102359. PMID:23202468
18. Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2015;60(1):6–13. doi:10.1128/AAC.01802-15. PMID:26438495
19. Van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, de Fougerolles A. Nanobodies® as inhaled biotherapeutics for lung diseases. 2016
20. Meeusen EL, Snibson KJ, Hirst SJ, Bischof RJ. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discov Today. 2009;6(4):101–6
21. Guillon, A., Sécher T, Dailey LA, Vecellio L, de Monte M, Si-Tahar M, Diot P, Page CP, Heuzé-Vourc'h N. Insights on animal models to investigate inhalation therapy: Relevance for biotherapeutics. Int J Pharm. 2018;536(1):116–26. doi:10.1016/j.ijpharm.2017.11.049. PMID:29180257
22. Cheng YS. Mechanisms of pharmaceutical aerosol deposition in the respiratory tract. AAPS PharmSciTech. 2014;15(3):630–40. doi:10.1208/s12249-014-0092-0. PMID:24563174
23. Harding R. Nasal obstruction in infancy. Aust Paediatr J. 1986;22(Suppl 1):59–61. PMID:3539080
24. Larios Mora A, Detalle L, Van Geelen A, Davis MS, Stohr T, Gallup JM, Ackermann MR. Kinetics of Respiratory Syncytial Virus (RSV) memphis strain 37 (M37) infection in the respiratory tract of newborn lambs as an RSV infection model for human infants. PLoS One. 2015;10(12):e0143580. doi:10.1371/journal.pone.0143580. PMID:26641081
25. Justicia-Grande AJ, Pardo-Seco J, Cebey-López M, Vilanova-Trillo L, Gómez-Carballa A, Rivero-Calle I, Puente-Puig M, Curros-Novo C, Gómez-Rial J, Salas A, Martinón-Sánchez JM, et al. Development and validation of a new clinical scale for infants with acute respiratory infection: the Resvinet scale. PLoS One. 2016;11(6):e0157665. doi:10.1371/journal.pone.0157665. PMID:27327497
26. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774–93. doi:10.1542/peds.2006-2223. PMID:17015575
27. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, Johnson DW, Light MJ, Maraqa NF, Mendonca EA, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–502. doi:10.1542/peds.2014-2742. PMID:25349312
28. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev. 2006;58(9–10):1030–60. doi:10.1016/j.addr.2006.07.012. PMID:17010473
29. Cooper AE, Ferguson D, Grime K. Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab. 2012;13(4):457–73. doi:10.2174/138920012800166571. PMID:22299825
30. Berthiaume L, Joncas J, Boulay G, Pavilanis V. Serological evidence of respiratory syncytial virus infection in sheep. Vet Rec. 1973;93(12):337–8. doi:10.1136/vr.93.12.337-a. PMID:4357318
31. Cutlip RC, Lehmkuhl HD. Lesions in lambs experimentally infected with bovine respiratory syncytial virus. Am J Vet Res. 1979;40(10):1479–82. PMID:525867
32. Derscheid RJ, van Geelen A, Gallup JM, Kienzle T, Shelly DA, Cihlar T, King RR, Ackermann MR. Human respiratory syncytial virus memphis 37 causes acute respiratory disease in perinatal lamb lung. Biores Open Access. 2014;3(2):60–9. doi:10.1089/biores.2013.0044. PMID:24804166
33. Ackermann MR. Lamb model of respiratory syncytial virus-associated lung disease: insights to pathogenesis and novel treatments. ILAR J / Natl Res Counc Inst Lab Anim Resour. 2014;55(1):4–15. doi:10.1093/ilar/ilu003
34. Villenave R, Thavagnanam S, Sarlang S, Parker J, Douglas I, Skibinski G, Heaney LG, McKaigue JP, Coyle PV, Shields MD, et al. In vitro modeling of respiratory syncytial virus infection of pediatric bronchial epithelium, the primary target of infection in vivo. Proc Natl Acad Sci U S A. 2012;109(13):5040–5. doi:10.1073/pnas.1110203109. PMID:22411804
35. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002;76(11):5654–66. doi:10.1128/JVI.76.11.5654-5666.2002. PMID:11991994
36. Mellow TE, Murphy PC, Carson JL, Noah TL, Zhang L, Pickles RJ. The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium. Exp Lung Res. 2004;30(1):43–57. doi:10.1080/01902140490252812. PMID:14967603
37. Tyrrell DA, Mika-Johnson M, Phillips G, Douglas WH, Chapple PJ. Infection of cultured human type II pneumonocytes with certain respiratory viruses. Infect Immun. 1979;26(2):621–9. PMID:232693
38. Peebles RS, Jr, Graham BS. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thoracic Soc. 2005;2(2):110–5. doi:10.1513/pats.200501-002AW
39. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, et al. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med. 2010;182(10):1305–14. doi:10.1164/rccm.201002-0221OC. PMID:20622030
40. DeVincenzo JP, El Saleeby CM, Bush AJ. Respiratory syncytial virus load predicts disease severity in previously healthy infants. J Infect Dis. 2005;191(11):1861–8. doi:10.1086/430008. PMID:15871119
41. Buckingham SC, Bush AJ, Devincenzo JP. Nasal quantity of respiratory syncytical virus correlates with disease severity in hospitalized infants. Pediatr Infect Dis J. 2000;19(2):113–7. doi:10.1097/00006454-200002000-00006. PMID:10693996
42. Lagos R, DeVincenzo JP, Muñoz A, Hultquist M, Suzich J, Connor EM, Losonsky GA. Safety and antiviral activity of motavizumab, a respiratory syncytial virus (RSV)-specific humanized monoclonal antibody, when administered to RSV-infected children. Pediatr Infect Dis J. 2009;28(9):835–7. doi:10.1097/INF.0b013e3181a165e4. PMID:19636278
43. Perkins SM, Webb DL, Torrance SA, El Saleeby C, Harrison LM, Aitken JA, Patel A, DeVincenzo JP. Comparison of a real-time reverse transcriptase PCR assay and a culture technique for quantitative assessment of viral load in children naturally infected with respiratory syncytial virus. J Clin Microbiol. 2005;43(5):2356–62. doi:10.1128/JCM.43.5.2356-2362.2005. PMID:15872266
44. Murray P, Laxton T, Alton C, Conibear B, Sargent T., Measurement of intracellular replicative strand in Respiratory Syncytial Virus (RSV) infected human volunteers, in Poster presentation at Molecular Med Tri-Con2016: San Francisco, CA
45. Devincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004;56(6):914–7. doi:10.1203/01.PDR.0000145255.86117.6A. PMID:15470202
46. Destino L, Weisgerber MC, Soung P, Bakalarski D, Yan K, Rehborg R, Wagner DR, Gorelick MH, Simpson P. Validity of respiratory scores in bronchiolitis. Hosp Pediatr. 2012;2(4):202–9. doi:10.1542/hpeds.2012-0013. PMID:24313026
47. Bekhof J, Reimink R, Brand PL. Systematic review: insufficient validation of clinical scores for the assessment of acute dyspnoea in wheezing children. Paediatr Respir Rev. 2014;15(1):98–112. PMID:24120749
48. Oymar K, Skjerven HO, Mikalsen IB. Acute bronchiolitis in infants, a review. Scand J Trauma Resusc Emerg Med. 2014;22:23. doi:10.1186/1757-7241-22-23. PMID:24694087
49. Miyaji Y, Sugai K, Nozawa A, Kobayashi M, Niwa S, Tsukagoshi H, Kozawa K, Noda M, Kimura H, Mori M. Pediatric respiratory severity score (PRESS) for respiratory tract infections in children. Austin Virol Retro Virol. 2015;2(1):1–7
50. Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, Lee S, Goleniewska K, Pretto C, Williams JV, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol. 2011;85(12):5782–93. doi:10.1128/JVI.01693-10. PMID:21471228
51. Houben ML, Coenjaerts FE, Rossen JW, Belderbos ME, Hofland RW, Kimpen JL, Bont L. Disease severity and viral load are correlated in infants with primary respiratory syncytial virus infection in the community. J Med Virol. 2010;82(7):1266–71. doi:10.1002/jmv.21771. PMID:20513094
52. Corneli HM, Zorc JJ, Mahajan P, Shaw KN, Holubkov R, Reeves SD, Ruddy RM, Malik B, Nelson KA, Bregstein JS, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med. 2007;357(4):331–9. doi:10.1056/NEJMoa071255. PMID:17652648
53. NICE Guideline, Bronchiolitis: diagnosis and management of bronchiolitis in children. 2015; Available from: https://www.nice.org.uk/guidance/ng9/evidence/full-guideline-pdf-64023661
54. Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care. 2009;54(11):1488–92. PMID:19863833
55. Goralski JL, Davis SD. Breathing easier: addressing the challenges of aerosolizing medications to infants and preschoolers. Respir Med. 2014;108(8):1069–74. doi:10.1016/j.rmed.2014.06.004. PMID:25012949
56. Kim YI, DeVincenzo JP, Jones BG, Rudraraju R, Harrison L, Meyers R, Cehelsky J, Alvarez R, Hurwitz JL. Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus. PLoS One. 2014;9(11):e113100. doi:10.1371/journal.pone.0113100. PMID:25415360
57. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711–22. doi:10.1056/NEJMoa1401184. PMID:25140957
58. DeVincenzo J., Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A. 2010;107(19):8800–5. doi:10.1073/pnas.0912186107. PMID:20421463
59. DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med. 2015;373(21):2048–58. doi:10.1056/NEJMoa1413275. PMID:26580997
60. Grosz DD, van Geelen A, Gallup JM, Hostetter SJ, Derscheid RJ, Ackermann MR. Sucrose stabilization of Respiratory Syncytial Virus (RSV) during nebulization and experimental infection. BMC Research Notes. 2014;7:158. doi:10.1186/1756-0500-7-158. PMID:24642084
61. Norton JR, Jackson PG, Taylor PM. Measurement of arterial oxygen-haemoglobin saturation in newborn lambs by pulse oximetry. Vet Rec. 1998;142(5):107–9. doi:10.1136/vr.142.5.107. PMID:9501385
62. Derscheid RJ, van Geelen A, McGill JL, Gallup JM, Cihlar T, Sacco RE, Ackermann MR. Human respiratory syncytial virus Memphis 37 grown in HEp-2 cells causes more severe disease in lambs than virus grown in Vero cells. Viruses. 2013;5(11):2881–97. doi:10.3390/v5112881. PMID:24284879
63. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol. 1986;60(2):532–8. doi:10.1152/jappl.1986.60.2.532. PMID:3512509
64. Conte JE, Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother. 1995;39(2):334–8. doi:10.1128/AAC.39.2.334. PMID:7726492
65. Furuie H, Saisho Y, Yoshikawa T, Shimada J. Intrapulmonary pharmacokinetics of S-013420, a novel bicyclolide antibacterial, in healthy Japanese subjects. Antimicrob Agents Chemother. 2010;54(2):866–70. doi:10.1128/AAC.00567-09. PMID:19933801
66. Allegranzi B, Cazzadori A, Di Perri G, Bonora S, Berti M, Franchino L, Biglino A, Cipriani A, Concia E. Concentrations of single-dose meropenem (1 g iv) in bronchoalveolar lavage and epithelial lining fluid. J Antimicrob Chemother. 2000;46(2):319–22. doi:10.1093/jac/46.2.319. PMID:10933662
67. Rodvold KA, Gotfried MH, Still JG, Clark K, Fernandes P. Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects. Antimicrob Agents Chemother. 2012;56(10):5076–81. doi:10.1128/AAC.00766-12. PMID:22802254